Roche's giredestrant demonstrated a 30% reduction in death or invasive disease recurrence risk in the Phase III lidERA trial for early-stage ER-positive breast cancer, with 92.4% of patients remaining alive and disease-free at three years versus 89.6% with standard endocrine therapy3
The lidERA trial became the first Phase III study of a selective estrogen receptor degrader (SERD) to show significant benefit in the adjuvant setting for early-stage breast cancer1
Giredestrant failed its primary endpoint in the Phase III persevERA trial as a first-line treatment when combined with Ibrance, though the drug showed numerical improvement in progression-free survival2
Despite the first-line setback, Roche pursued FDA approval based on second-line trial data and planned to submit adjuvant data to the agency2
Analysts previously forecast giredestrant could achieve peak sales of 5 billion Swiss francs ($6.4 billion) in 2030 based on early positive results, though the first-line trial failure challenged more optimistic multi-billion dollar sales projections2
The drug's consistent benefit across patient subgroups in early-stage disease and positive trend in overall survival suggest potential as a new standard-of-care endocrine therapy despite clinical trial setbacks in other settings3
Sources:
1. https://www.roche.com/media/releases/med-cor-2025-11-18
2. https://www.fiercebiotech.com/biotech/roches-oral-serd-flunks-phase-3-trial-first-line-breast-cancer
3. https://www.biospace.com/drug-development/roches-oral-serd-cuts-death-risk-by-30-in-early-stage-breast-cancer